Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Dova Pharmaceuticals Inc (DOVA)

Dova Pharmaceuticals Inc (DOVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 807,608
  • Shares Outstanding, K 28,802
  • Annual Sales, $ 10,360 K
  • Annual Income, $ -72,280 K
  • 60-Month Beta 2.74
  • Price/Sales 77.88
  • Price/Cash Flow N/A
  • Price/Book 15.58
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.56
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/14/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.64
  • Number of Estimates 3
  • High Estimate -0.61
  • Low Estimate -0.66
  • Prior Year -0.69
  • Growth Rate Est. (year over year) +7.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.93 +0.39%
on 11/07/19
28.54 -1.75%
on 10/31/19
-0.36 (-1.27%)
since 10/11/19
3-Month
14.18 +97.74%
on 08/26/19
28.54 -1.75%
on 10/31/19
+12.03 (+75.14%)
since 08/09/19
52-Week
5.62 +398.93%
on 12/20/18
28.54 -1.75%
on 10/31/19
+11.15 (+66.02%)
since 11/09/18

Most Recent Stories

More News
Dova Granted Orphan Drug Designation for Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia

Dova Pharmaceuticals, Inc., a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi(TM)), has been granted Orphan Drug Designation1 (ODD) by the US Food and Drug Administration (FDA) for...

SWTUY : 24.3800 (-1.18%)
DOVA : 28.04 (+0.14%)
FDA Grants Avatrombopag Orphan Drug Designation for the Treatment of Chemotherapy-induced Thrombocytopenia

Dova Pharmaceuticals, Inc., a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi(TM)) has been granted Orphan Drug Designation[1] (ODD) by the US Food and Drug Administration (FDA) for...

SWTUY : 24.3800 (-1.18%)
DOVA : 28.04 (+0.14%)
Additional Analyses From Phase 3 study With Doptelet ® (avatrombopag) for the treatment of Chronic Immune Thrombocytopenia Provides Evidence of Long-term Response Rates

Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi(TM)), presented additional analyses from the phase 3 study - core and extension phase - with avatrombopag (AVA)...

SWTUY : 24.3800 (-1.18%)
DOVA : 28.04 (+0.14%)
Doptelet ® (avatrombopag) Demonstrates Cost-effectiveness for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease

Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi(TM)), presented data on the cost effectiveness of Doptelet® (avatrombopag) for the treatment of thrombocytopenia...

SWTUY : 24.3800 (-1.18%)
DOVA : 28.04 (+0.14%)
Results from a Survey With Patients With Immune Thrombocytopenia (ITP) Demonstrates Disease Burden and Impact for Patients With ITP

Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi(TM)), presented results from an online survey highlighting disease burden and impact for patients with immune...

SWTUY : 24.3800 (-1.18%)
DOVA : 28.04 (+0.14%)
Data to be Highlighted at the American Society of Hematology 2019 Annual Meeting

Sobi(TM) and its wholly owned subsidiary Dova Pharmaceuticals, will present new data from studies with avatrombopag for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD)...

DOVA : 28.04 (+0.14%)
Sobi Successfully Completes Acquisition of Dova Pharmaceuticals

Swedish Orphan Biovitrum AB (publ) (Sobi(TM)) (STO: SOBI) and Dova Pharmaceuticals, Inc. (Dova) (NASDAQ: DOVA) announced today the completion of the acquisition of Dova by Sobi.

SWTUY : 24.3800 (-1.18%)
DOVA : 28.04 (+0.14%)
Sobi Successfully Completes Tender Offer for All Outstanding Shares of Dova Pharmaceuticals

Swedish Orphan Biovitrum AB (publ) (Sobi(TM)) (STO: SOBI) announced today that its indirect wholly owned subsidiary Dragonfly Acquisition Corp. (Dragonfly) has successfully completed its tender offer to...

SWTUY : 24.3800 (-1.18%)
DOVA : 28.04 (+0.14%)
Will Dova Pharmaceuticals (DOVA) Report Negative Q3 Earnings? What You Should Know

Dova Pharmaceuticals (DOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DOVA : 28.04 (+0.14%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds DOVA, TRCB, EEI, and UCFC Shareholders About Its Ongoing Investigations

EQNX::TICKER_START (NasdaqGM:DOVA),(NasdaqGM:TRCB),(NasdaqGM:EEI),(NASDAQ:UCFC), EQNX::TICKER_END

DOVA : 28.04 (+0.14%)
TRCB : 22.40 (+0.45%)
EEI : 15.45 (+1.91%)
UCFC : 11.58 (-1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade DOVA with:

Business Summary

Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company's drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals,...

See More

Key Turning Points

2nd Resistance Point 28.27
1st Resistance Point 28.15
Last Price 28.04
1st Support Level 27.96
2nd Support Level 27.89

See More

52-Week High 28.54
Last Price 28.04
Fibonacci 61.8% 19.78
Fibonacci 50% 17.08
Fibonacci 38.2% 14.38
52-Week Low 5.62

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar